Tisagenlecleucel for the treatment of patients with follicular lymphoma after two or more therapies

NICE

22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults with relapsed or refractory follicular lymphoma after two or more therapies. 

This is because Novartis did not provide an evidence submission.

Read NICE technology appraisal

Michael Wonder

Posted by:

Michael Wonder